Genetics

TelVysion DNA Probes Available To Detect Abnormalities

Published in Gene Therapy Weekly, July 27th, 1998

Vysis, Inc., Downers Grove, Illinois, announced the availability of its first group of TelVysion DNA probes for the detection of genetic abnormalities involving telomeres for prenatal, congenital and cancer research.

The TelVysion probes utilize Vysis' Fluorescence In Situ Hybridization (FISH) technology to visually detect cryptic, difficult to identify translocations associated with cancer and other diseases.

Designed for research use only, Vysis' TelVysion probes were developed in connection with a research and exclusive license agreement with The University of Chicago, Illinois, which was announced in September 1997. Vysis' TelVysion DNA probes...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-07-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry